Peptide
Semaglutide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Un tudalen y meddyginiaeth. Maintau effaith, dyluniadau treialon, a'r poblogaethau y mesurwyd ynddynt.
Peptide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Dual agonist
SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.
Oral
Oral semaglutide and orforglipron — the same mechanism without the injection.
Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep, circadian rhythm and the wearables that claim to measure both.
Cafodd y dudalen hon ei thrawsgrifiad yn awtomatig o Saesneg. Mae'r dyfyniadau a'r rhifau heb newid. Darllenwch y gwreiddiol Saesneg os yw unrhyw beth yn darllen yn rhy ddieithr. Darllenwch y gwreiddiol Saesneg